Neoadjuvant checkpoint blockade for cancer immunotherapy

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancer immunotherapies that target the programmed cell death 1 (PD-1):programmed death-ligand 1 (PD-L1) immune checkpoint pathway have ushered in the modern oncology era. Drugs that block PD-1 or PD-L1 facilitate endogenous antitumor immunity and, because of their broad activity spectrum, have been regarded as a common denominator for cancer therapy. Nevertheless, many advanced tumors demonstrate de novo or acquired treatment resistance, and ongoing research efforts are focused on improving patient outcomes. Using anti–PD-1 or anti–PD-L1 treatment against earlier stages of cancer is hypothesized to be one such solution. This Review focuses on the development of neoadjuvant (presurgical) immunotherapy in the era of PD-1 pathway blockade, highlighting particular considerations for biological mechanisms, clinical trial design, and pathologic response assessments. Findings from neoadjuvant immunotherapy studies may reveal pathways, mechanisms, and molecules that can be cotargeted in new treatment combinations to increase anti–PD-1 and anti–PD-L1 efficacy.

Original languageEnglish (US)
Article numbereaax0182
JournalScience
Volume367
Issue number6477
DOIs
StatePublished - Jan 31 2020

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Neoadjuvant checkpoint blockade for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this